Trends in hepatitis B virus seroprevalence in a large cohort of adult cancer patients from 2010 to 2023.

Authors

Marina Rossi de Camargo Pinto, Victória Gonçalves de Paula, Débora Bignotto Rosane Battaglia, Rafael de Oliveira, Gustavo Manoel Ferreira, Caroline Manchiero, Bianca Peixoto Dantas, Fátima Mitiko Tengan, Edson Abdala, Mariana Cavalheiro Magri

Published in

Cancer causes & control : CCC. Volume 37. Issue 10. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

Hepatitis B virus (HBV) infection poses increased risks for cancer patients due to immunosuppression and potential viral reactivation. We evaluated the seroprevalence and temporal trends of HBV exposure in a large cohort of cancer patients in Brazil.
Adult patients who underwent anti-HBc testing at a quaternary oncology center between 2010 and 2023 were included in this retrospective study, and HBV exposure was defined as anti-HBc positivity. Temporal trends were assessed by using linear regression, whereas associated factors were evaluated by using multivariable logistic regression.
Anti-HBc testing was performed in 22.9% (28,869/125,985) of admitted cancer patients, and seroprevalence was 13.4% (3,857/28,869), declining from 16.5 in 2010 to 9.9% in 2023 (p < 0.001). Decreasing trends were observed across sexes and age groups (p < 0.001 for both), with a more pronounced decline among men (25.1%-12.3%). Seroprevalence also decreased significantly among White patients (16.7%-7.9%; p < 0.001) and those with solid tumors (18.8%-9.0%; p < 0.001), but not among non-White individuals (21.4%-17.7%; p = 0.246) or those with hematological malignancies (13.1%-12.8%; p = 0.136). Age ≥ 60 years (OR = 4.40; 95%CI: 3.77-5.12; p < 0.001), men (OR = 1.89; 95%CI: 1.76-2.04; p < 0.001), and non-White ethnicity/color (OR = 1.25; 95%CI: 1.15-1.35; p < 0.001) were independently associated with HBV exposure.
Despite the declining seroprevalence over time, HBV exposure remains common among cancer patients, as persistent disparities across demographic groups underscore the need for expanded vaccination and systematic screening.

PMID:
42842036
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.